Recent advances in the management of multiple myeloma

Seminars in Hematology

Volumn 41, Issue 2 SUPPL. 4, 2004, Pages 21-26

  Munshi, Nikhil C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; BORTEZOMIB; CYTOKINE; DEXAMETHASONE; DOXORUBICIN; IMMUNOMODULATING AGENT; INTERLEUKIN 21; INTERLEUKIN 6; LENALIDOMIDE; MELPHALAN; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN; RAS PROTEIN; SOMATOMEDIN B; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANEMIA; ANTINEOPLASTIC ACTIVITY; CANCER STAGING; CELL GROWTH; CELL SURVIVAL; CLINICAL TRIAL; CONSTIPATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; FATIGUE; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOMODULATION; MICROENVIRONMENT; MULTIPLE MYELOMA; NEUROLOGIC DISEASE; NEUROPATHY; NEUTROPENIA; OUTCOMES RESEARCH; PRIORITY JOURNAL; REVIEW; SOMNOLENCE; THROMBOEMBOLISM; TUMOR CELL;

EID: 2442596893     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2004.03.002     Document Type: Article

References (37)

1. Barlogie B, Shaughnessy J, Tricot G, et al: Treatment of multiple myeloma. Blood 103:20-32, 2004
2. Myeloma Trialists' Collaborative Group: Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials. J Clin Oncol 16:3832-3842, 1998
3. Lenhoff S, Hjorth M, Holmberg E, et al: Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: A population-based study. Nordic Myeloma Study Group. Blood 95:7-11, 2000
4. Attal M, Harousseau JL, Stoppa AM, et al: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335:91-97, 1996
5. Child JA, Morgan GJ, Davies FE, et al: High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348:1875-1883, 2003
6. Attal M, Harousseau JL, Facon T, et al: Double autologous transplantation improves survival of multiple myeloma patients: Final analysis of a prospective randomized study of the "Intergroupe Francophone du Myelome" (IFM 94). Blood 100:5a-6a, 2002 (abstr)
7. 2 + tbi 12 gy autotransplants versus standard dose therapy with vbmcp and no benefit from interferon (ifn) maintenance: Results of intergroup trial s9321. Blood 102:42a, 2003 (abstr)
8. Blade J, Vesole DH, Gertz M: High-dose therapy in multiple myeloma. Blood 102:3469-3470, 2003
9. Fermand JP, Ravaud P, Chevret S, et al: High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 92: 3131-3136, 1998
10. Urashima M, Chauhan D, Uchiyama H, et al: CD40 ligand triggered interleukin-6 secretion in multiple myeloma. Blood 85:1903-1912, 1995
11. Urashima M, Ogata A, Chauhan D, et al: Transforming growth factor-beta1: Differential effects on multiple myeloma versus normal B cells. Blood 87:1928-1938, 1996
12. Chauhan D, Uchiyama H, Akbarali Y, et al: Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 87:1104-1112, 1996
13. Raje N, Anderson K: Thalidomide - A revival story. N Engl J Med 341:1606-1609, 1999
14. Weber D: Thalidomide and its derivatives: New promise for multiple myeloma. Cancer Control 10:375-383, 2003
15. Singhal S, Mehta J, Desikan R, et al: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565-1571, 1999
16. Barlogie B, Desikan R, Eddlemon P, et al: Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. Blood 98:492-494, 2001
17. Yakoub-Agha I, Attal M, Dumontet C, et al: Thalidomide in patients with advanced multiple myeloma: A study of 83 patients - Report of the Intergroupe Francophone du Myelome (IFM). Hematol J 3:185-192, 2002
18. Weber D, Rankin K, Gavino M, et al: Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21:16-19, 2003
19. Palumbo A, Giaccone L, Bertola A, et al: Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 86:399-403, 2001
20. Dimopoulos MA, Zervas K, Kouvatseas G, et al: Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 12:991-995, 2001
21. Rajkumar SV, Hayman S, Gertz MA, et al: Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 20:4319-4323, 2002
22. Richardson PG, Schlossman RL, Weller E, et al: Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100:3063-3067, 2002
23. Hideshima T, Chauhan D, Shima Y, et al: Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96:2943-2950, 2000
24. Gupta D, Treon SP, Shima Y, et al: Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: Therapeutic applications. Leukemia 15:1950-1961, 2001
25. Davies FE, Raje N, Hideshima T, et al: Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98:210-216, 2001
26. Myung J, Kim KB, Crews CM: The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev 21:245-273, 2001
27. DeMartino GN, Slaughter CA: The proteasome, a novel protease regulated by multiple mechanisms. J Biol Chem 274: 22123-22126, 1999
28. Munshi NC, Hideshima T, Carrasco D, et al: Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood 103:1799-1806, 2003
29. Hideshima T, Richardson P, Chauhan D, et al: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071-3076, 2001
30. Richardson PG, Barlogie B, Berenson J, et al: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617, 2003
31. Blade J, Samson D, Reece D, et al: Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 102:1115-1123, 1998
32. Hayashi T, Hideshima T, Akiyama M, et al: Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther 1:851-860, 2002
33. Grad JM, Bahlis NJ, Reis I, et al: Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood 98:805-813, 2001
34. Munshi NC, Tricot G, Desikan R, et al: Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia 16:1835-1837, 2002
35. Hussein MA, Mason J, Saleh MN, et al: Arsenic trioxide (Trisenox) in patients with relapsed or refractory multiple myeloma (MM): Final report of a phase II clinical study. Blood 100:393b, 2002 (abstr)
36. Borad M, Swift RA, Sadler K, et al: Melphalan, arsenic trioxide and ascorbic acid (mac) is effective in the treatment of refractory and relapsed multiple myeloma (mm). Blood 102:235a-236a, 2003 (abstr)
37. Hussein M, Elson P, Reed J, et al: Clinical experience with Trisenox (arsenic trioxide) in combination with ascorbic acid (AA) and dexamethasone (DEX). Poster presented at the 8th Congress of the European Hematology Association, Lyon, France, June 12-15, 2003